Jinan Zhuocheng Bio-Tech Co., Ltd.

A series of recent regulatory actions by China’s pharmaceutical authorities has drawn significant attention across the global pharmaceutical industry. Following the suspension of Amlodipine Besylate API imports from Cadila Pharmaceuticals Limited in April 2026, China’s National Medical Products Administration (NMPA) has continued intensifying oversight, with several well-known Indian pharmaceutical companies now facing import suspensions.

Why are APIs once regarded as highly competitive “Indian pharmaceutical products” suddenly encountering repeated regulatory barriers in China? The issue goes far beyond simple quality concerns—it reflects China’s transition into an era of increasingly stringent pharmaceutical regulation.

01 | On-Site GMP Inspections Reveal Serious Compliance Violations

The latest regulatory wave began in early April 2026, when the NMPA announced the suspension of importation, sale, and use of Amlodipine Besylate API manufactured by Cadila Pharmaceuticals Limited.

Inspection findings revealed multiple serious GMP compliance issues, including:

• Inconsistencies between actual production sites and registered manufacturing addresses

• Unauthorized process modifications without regulatory notification

• Production processes inconsistent with approved manufacturing procedures

At nearly the same time, APIs produced by Vasudha Pharm Chem Limited and Alchem International, including Loperamide Hydrochloride, Reserpine, and Digoxin, were also suspended from import into China.

These are not niche products—they are critical APIs used in antihypertensive drugs, antidiarrheal medications, and cardiovascular therapies widely consumed in clinical practice.

Amlodipine Besylate, in particular, is a major antihypertensive drug widely included in China’s centralized procurement system, meaning API quality directly affects the safety of millions of patients.

02 | New Regulations Signal “Equal Supervision” for Domestic and Overseas Manufacturers

Many industry observers are asking why China has recently intensified regulatory enforcement so aggressively.

The answer lies in the revised Implementation Regulations of the Drug Administration Law of the People’s Republic of China, scheduled to take effect on May 15, 2026.

The revised regulation emphasizes a clear principle:

Domestic and overseas pharmaceutical manufacturers will be subject to the same regulatory standards.

The updated rules strengthen accountability for Marketing Authorization Holders (MAHs) while explicitly extending Chinese regulatory requirements to overseas pharmaceutical manufacturing activities.

This means that APIs and pharmaceutical products marketed in China—regardless of where they are produced—must fully comply with Chinese laws and GMP standards.

Practices previously considered “flexible” by some overseas manufacturers, such as changing production sites or consolidating production lines without notification, are no longer tolerated under China’s increasingly strict compliance framework.

03 | Is China Still Highly Dependent on Indian APIs?

For years, many believed that Indian APIs were indispensable to China’s pharmaceutical supply chain due to their competitive pricing and large-scale production capacity.

However, recent developments suggest the situation may be changing.

According to statistics from the China Chamber of Commerce for Import & Export of Medicines & Health Products, China’s API imports reached USD 12.38 billion in 2025, up 14.5% year-on-year. While India remains an important supplier, imports are increasingly concentrated in specific intermediates rather than irreplaceable finished APIs.

The suspension of Amlodipine Besylate APIs also demonstrates that China’s domestic production capacity has significantly improved. Domestic manufacturers are now capable of meeting market demand for many major APIs.

China’s confidence in taking regulatory action against large overseas suppliers reflects the growing maturity and resilience of its local API industry, strengthened through years of generic drug consistency evaluation and centralized procurement reforms.

04 | Pharmaceutical Regulation Is Also Becoming Part of Trade Competition

The tightening regulatory environment also comes amid a sensitive international trade backdrop.

Recently, India’s Ministry of Commerce has launched multiple anti-dumping investigations targeting Chinese pharmaceutical intermediates. Against this backdrop, China’s enhanced scrutiny of imported Indian APIs can also be viewed as part of broader reciprocal trade compliance dynamics.

Pharmaceutical regulation is no longer purely a technical matter—it has increasingly become intertwined with international industrial competition and trade policy.

Industry experts note that while these inspections are fundamentally routine GMP enforcement actions, they also indirectly encourage China’s pharmaceutical industry to reduce dependence on single overseas suppliers and accelerate supply chain localization and diversification.

05 | Compliance Is Becoming the Ultimate Competitive Barrier

For overseas pharmaceutical companies seeking access to China’s market—and for domestic pharmaceutical manufacturers relying on imported APIs—this latest regulatory wave sends a strong warning.

For Indian pharmaceutical companies:

Establishing a China-specific compliance system is no longer optional. Meeting U.S. FDA or Indian standards alone is insufficient; compliance with China’s NMPA GMP requirements is mandatory and independently enforced.

For example, Vasudha Pharm Chem Limited had previously faced import suspension in 2019 and only resumed market access in 2025 after extensive rectification efforts—highlighting the enormous cost of regulatory non-compliance.

For Chinese pharmaceutical companies:

The window for import substitution is rapidly opening.

As the industry increasingly moves toward integrated “API + formulation” models, domestic API manufacturers with stable production capacity and strong quality systems are expected to benefit significantly.

China’s recent regulatory actions are not targeted at any single country. Instead, they represent a broader transformation as China evolves from a “major pharmaceutical producer” into a true “pharmaceutical powerhouse.”

As reflected in the revised Drug Administration Law implementation regulations:

There is no distinction between domestic and foreign when it comes to drug safety—only compliant and non-compliant products.

For every pharmaceutical company seeking entry into the Chinese market, the message is becoming increasingly clear:

China welcomes competition, but not regulatory shortcuts. The market is enormous—but so are the compliance requirements.